The effectiveness of dapagliflozin versus furosemide in controlling blood pressure in uncontrolled hypertension with subclinical fluid retention in chronic kidney disease

Phase 4

• Conditions: ncontrolled hypertension with subclinical fluid retention in chronic kidney disease; Urological and Genital Diseases

• Registration Number: ISRCTN14012970
• Lead Sponsor: Bhumibol Adulyadej Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-01-12
• Last Update Posted: 22 April 2024
• Study Completion: 2024-08-15

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

Current inclusion criteria as of 12/04/2024:
1. Age from 18 years old
2. Chronic kidney disease (GFR-EPI 20-60 ml/min/1.73m2)
3. Uncontrolled hypertension with fluid retention detected by bioimpedance

Previous inclusion criteria:
1. Age from 18 years old
2. Chronic kidney disease (GFR-EPI 20-60 ml/min/1.73m2)
3. Resistant hypertension

Exclusion Criteria

Current exclusion criteria as of 12/04/2024:
1. Patient receiving diuretics or SGLT2i
2. Uncontrolled HT with euvolemic status
3. Life expectancy <12 months (principal investigator’s judgement)
4. Living-donor transplant scheduled within the next 12 months
5. Cardiovascular disease (dilated cardiomyopathy, valvular heart disease)
6. Active infection
7. Current active malignancy
8. Known HIV or active hepatitis B or C
9. Chronic liver disease and/or screening alanine transaminase or aspartate transaminase above 3 times the upper limit of the normal range
10. Pregnancy or breastfeeding
11. Subject has any kind of disorder that compromises their ability to informed consent and/or to comply with study procedures

Previous exclusion criteria:
1. Life expectancy less than 12 months
2. Living-donor transplant scheduled within the next 12 months
3. Cardiovascular disease (dilated cardiomyopathy, valvular heart disease)
4. Active infection
5. Current active malignancy
6. Known HIV or active hepatitis B or C
7. Chronic liver disease and/or screening alanine transaminase or aspartate transaminase above 3 times the upper limit of the normal range
8. Pregnancy or breastfeeding
9. Subject has any kind of disorder that compromises their ability to informed consent and/or to comply with study procedures

Study & Design

• Study Type: Interventional
• Study Design: Not specified